Oxford BioDynamics PLC PDMR Dealing (6120K)

TIDMOBD

RNS Number : 6120K

Oxford BioDynamics PLC

29 August 2019

29 August 2019

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing

Oxford BioDynamics Plc (AIM: OBD) announces that it has today received notice that Vulpes Life Sciences Fund, which is controlled by Non-Executive Director, Stephen Diggle, has purchased 4,500 Ordinary Shares of 1 pence each at a price of 90p per share.

Following this transaction, Vulpes Life Sciences Fund is interested in 11,734,725 Ordinary Shares, representing approximately 12.68% of the Company's current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             Stephen Diggle 
     -------------------------------  -------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Director/PDMR 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/            Initial notification 
       Amendment 
     -------------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             Oxford BioDynamics Plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              2138005Y1TK258O5U928 
     -------------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 1 pence each 
       financial instrument,            ISIN: GB00BD5H8572 
       type of instrument 
       Identification code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the transaction        Acquisition of ordinary shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)             Price(s)   Volume(s) 
                                          0.90       4,500 
                                                    ---------- 
     -------------------------------  -------------------------------------- 
 d)   Aggregated information             Price   Volume 
       - Aggregated volume                0.90    4,500 
       - Price                                   ------- 
     -------------------------------  -------------------------------------- 
 e)   Dates of the transactions        28 August 2019 
     -------------------------------  -------------------------------------- 
 f)   Place of the transaction         Outside a trading venue 
     -------------------------------  -------------------------------------- 
 

For further details please contact:

 
 Oxford BioDynamics Plc 
  Christian Hoyer Millar, 
  CEO 
  Paul Stockdale, CFO              [phone] 
 Shore Capital 
  Nominated Adviser and Broker 
  Stephane Auton 
  Edward Mansfield                [phone] 
 FTI Consulting 
  Financial Public Relations 
  Adviser 
  Brett Pollard 
  Natalie Garland-Collins         [phone] 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHPLMITMBTTBPL

(END) Dow Jones Newswires

August 29, 2019 10:30 ET (14:30 GMT)